Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 13, Number 7—July 2007


Antimicrobial Drugs and Community-acquired Methicillin-Resistant Staphylococcus aureus, United Kingdom

Verena Schneider-Lindner*†, J. A. Delaney*†, Sandra Dial†‡, Andre Dascal‡, and Samy Suissa*†Comments to Author 
Author affiliations: *McGill University Health Center, Montreal, Quebec, Canada; †Royal Victoria Hospital, Montreal, Quebec, Canada; ‡Sir Mortimer B. Davis–Jewish General Hospital, Montreal, Quebec, Canada;

Main Article

Table 4

Sensitivity analysis for the clinical code used to define methicillin-resistant Staphylococcus aureus (MRSA)*

Clinical code† Case-patients
Crude OR Adjusted OR‡ 95% CI
N (%) % Exposed N % Exposed
Any code 1,981 (100) 61.1 19,779 35.2 2.98 2.61 2.36–2.89
4JP..00 1,735 (85.5) 62.2 17,327 35.7 3.05 2.66 2.39–2.97
SP25800 157 (8.8) 60.5 1,570 32.7 3.34 2.99 2.06–4.33
ZV02A00 113 (5.7) 47.8 1,122 30.5 2.09 1.98 1.30–3.01

*Risk for MRSA diagnosed in the community for persons with any number of antimicrobial drug prescriptions (exposed) in the 30–365 days before their index date relative to risk for MRSA for persons with no prescriptions during the same period. Data from 4 different analyses of a matched case-control study of patients listed in the General Practice Research Database, UK, 2000–2004. OR, odds ratio; CI, confidence interval.
†4JP..00, MRSA positive; SP25800, MRSA infection of postoperative wound; ZV02A00, [V]MRSA multiple-resistant Staphylococcus aureus infection carrier.
‡Adjusted for all covariates in Table 1.

Main Article